Table 5.
NCBI rs# | Location | Variant | Genotype | Frequency | Allele-dose | Dominant* | Recessive# | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||
without NIHL (-) | with NIHL (+) | P | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | ||||
rs208679 | 5’flanking | A/G | AA | 170 (56.40) | 72 (58.10) | 0.89 | 1.03 (0.73~1.25) | 0.83 | 1.07 (0.70~1.63) | 0.83 | 0.90 (0.40~2.04) |
AG | 112 (37.00) | 43 (34.70) | |||||||||
GG | 20 (6.60) | 9 (7.30) | |||||||||
rs10836233 | 5’flanking | G/A | GG | 155 (51.30) | 71 (57.30) | 0.41 | 0.88 (0.64~1.23) | 0.29 | 0.79 (0.52~1.20) | 0.75 | 1.10 (0.58~2.06) |
GA | 113 (37.40) | 38 (30.60) | |||||||||
AA | 34 (11.30) | 15 (12.10) | |||||||||
rs2300182 | Intron1 | T/A | TT | 203 (67.00) | 88 (71.00) | 0.36 | 0.79 (0.53~1.18) | 0.49 | 0.83 (0.53~1.31) | 0.25 | 0.37 (0.08~1.65) |
TA | 87 (28.70) | 34 (27.40) | |||||||||
AA | 13 (4.30) | 2 (1.60) | |||||||||
rs769217 | exon9 (synon) | T/C | TT | 61 (20.10) | 31 (37.10) | 0.02 | 1.11 (0.82~1.49) | 0.048 | 1.59 (1.02~2.48) | 0.30 | 0.76 (0.46~1.24) |
TC | 160 (52.80) | 47 (37.90) | |||||||||
CC | 82 (27.10) | 46 (25.00) | |||||||||
rs7104301 | 3’flanking | A/G | AA | 173 (57.10) | 69 (55.60) | 0.18 | 0.85 (0.61~1.19) | 0.83 | 0.94 (0.62~1.44) | 0.08 | 0.49 (0.22~1.07) |
AG | 115 (38.00) | 43 (34.70) | |||||||||
GG | 15 (5.00) | 12 (9.70) | |||||||||
rs7949972 | 3’flanking | C/T | CC | 104 (34.30) | 46 (37.10) | 0.75 | 1.03 (0.76~1.38) | 0.58 | 1.16 (0.75~1.79) | 0.69 | 0.89 (0.53~1.50) |
CT | 140 (46.20) | 52 (41.90) | |||||||||
TT | 59 (19.50) | 26 (21.00) |
Dominant effect = variant homozygotes + heterozygotes versus wild-type homozygotes;
Recessive effect = variant homozygotes versus heterozygotes + wild-type homozygotes.